Alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone inhibitors of ribonucleoside diphosphate reductase.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000201:enzymology; D003562:Cytidine / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003854:Deoxyribonucleotides / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005557:Formaldehyde / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000201:enzymology; D051379:Mice; D009374:Neoplasms, Experimental / Q000201:enzymology*; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000096:biosynthesis; D051381:Rats; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D012265:Ribonucleotides / Q000096:biosynthesis; D012510:Sarcoma 180 / Q000188:drug therapy / Q000378:metabolism; D013882:Thiosemicarbazones / Q000494:pharmacology* / Q000627:therapeutic use; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D003854:Deoxyribonucleotides; D007546:Isoquinolines; D011725:Pyridines; D012334:RNA, Neoplasm; D012265:Ribonucleotides; D013882:Thiosemicarbazones; D014316:Tritium; D005557:Formaldehyde; D003562:Cytidine; D012264:Ribonucleotide Reductases; D013936:Thymidine